KBC Group NV Decreases Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

KBC Group NV lowered its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 2.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 407,518 shares of the medical device company's stock after selling 10,170 shares during the quarter. KBC Group NV owned approximately 0.10% of DexCom worth $27,830,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in DXCM. Norges Bank bought a new stake in shares of DexCom during the 4th quarter valued at about $385,367,000. Woodline Partners LP bought a new stake in DexCom during the 4th quarter valued at approximately $63,338,000. Northern Trust Corp grew its holdings in shares of DexCom by 22.2% during the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock worth $322,454,000 after acquiring an additional 753,857 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of DexCom during the 4th quarter worth approximately $41,295,000. Finally, GAMMA Investing LLC raised its position in shares of DexCom by 5,951.7% in the 1st quarter. GAMMA Investing LLC now owns 499,746 shares of the medical device company's stock worth $34,128,000 after acquiring an additional 491,488 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Price Performance

Shares of DXCM traded down $0.76 during mid-day trading on Thursday, reaching $82.83. The stock had a trading volume of 1,840,682 shares, compared to its average volume of 4,388,816. The firm has a market cap of $32.48 billion, a price-to-earnings ratio of 61.93, a PEG ratio of 1.78 and a beta of 1.44. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. The business has a fifty day moving average of $82.80 and a 200 day moving average of $79.71. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $117.19.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The business had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same period in the prior year, the firm posted $0.32 earnings per share. The firm's revenue for the quarter was up 12.5% on a year-over-year basis. Equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on DXCM. Citigroup restated a "buy" rating and set a $102.00 target price (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Mizuho began coverage on shares of DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 price objective for the company. Barclays boosted their price target on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Robert W. Baird lowered their price objective on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group began coverage on DexCom in a research report on Friday, May 30th. They issued a "buy" rating and a $104.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $98.50.

Insider Activity at DexCom

In related news, Director Nicholas Augustinos sold 3,672 shares of the company's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the transaction, the director owned 33,411 shares in the company, valued at approximately $2,766,430.80. This represents a 9.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction on Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $41,400.00. Following the completion of the sale, the executive vice president owned 95,102 shares in the company, valued at approximately $7,874,445.60. This represents a 0.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 27,190 shares of company stock worth $2,281,732. 0.32% of the stock is currently owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.